For example, TanCAR T-cells that target both HER2 and CD19 have demonstrated the capacity to destroy tumor cells expressing either antigen while releasing key effector molecules like IFN-γ and IL-2 [48,49]. This evidence concerns the gene ERBB2 and neoplasm.